Peter Kolchinsky, Ph.D. - Forma Therapeutics Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. He also serves on the board of the American . Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Lucas Guevara is a Compliance Counsel at RA Capital Management. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Hearing the stories of how patients couldn't afford the . Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Prior to RA, Ryan was at KPMG where he was a Senior Associate. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Our website uses cookies to distinguish you from other users of our website. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. She previously worked as a Finance Associate at the MFA Companies. He previously served as the CFO of Research Alliance Corp I before its merger with Point Biopharma and served on the boards of Research Alliance Corp I and Research Alliance Corp II. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Steve's survey is fascinating. Laura previously worked at WinterWyman where she served as a Senior Associate. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Jon's primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Brendans primary responsibility is managing all aspects of the tax function. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). He holds a BS in Finance from Providence College. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Adam was also an advisor and investor in A Late Quartet, an entrepreneurial feature film centered on a cellist diagnosed with Parkinsons disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Biotech's Dulcius Ex Asperis: The Way Through This Downturn Most recently, Tom served as Director of Operations at TPRV Capital, LP. Peter Kolchinsky was born in the United States of America. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Jeff holds a BA in Economics and Psychology from Georgetown. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.